Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
收藏DataCite Commons2024-11-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003858/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when given as a second dose to children four to six years of age.
提供机构：
Vivli
创建时间：
2019-04-22
